This study aims to investigate the value of 68Ga-grazytracer in predicting the efficacy of immunotherapy for advanced hepatobiliary malignancies.
Pathological and clinical diagnosis of advanced hepatobiliary malignancy requiring immunotherapy or combination immunotherapy after evaluation according to clinical guidelines
Signed and dated informed consent form
Commitment to comply with research procedures and co-operation in the implementation of the full research process
aged 18-75 years old
Patients with serious illnesses that researchers consider unsuitable for participation in this clinical study. Such as severe heart and lung failure, severe bone marrow suppression, severe liver and kidney dysfunction, etc.
Intestinal perforation, complete intestinal obstruction
Uncontrolled diabetes patients or fasting blood glucose levels ≥11 mmol/L on the day of the trial
Pregnant women and women who may be pregnant, women who are breastfeeding.
Inpatients and outpatients at Ruijin Hospital who meet the inclusion criteria.
Other
Prospective
Not listed
Evaluation the responses to immunotherapy of advanced hepatobiliary malignancy
The value of 68Ga-grazytracer PET in monitoring responses to immunotherapy of advanced hepatobiliary malignancy
Standardized uptake value(SUV)
SUV of 68Ga-grazytracer uptake on PET/CT images for tumor lesions
Target-to-background ratio(TBR)
68Ga-grazytracer uptake ratio of tumor lesions to mediastinum and liver blood pool on PET/CT images.
Progress free survival
Progress free survival
Overall survival
Overall survival
Click on the lead sponsor to view all of their trials.
